Study of cagrilintide for weight reduction in adults with overweight or obesity when combined with lifestyle changes

1 1

What is this study about?

This study focuses on people with obesity or overweight, which are medical conditions where a person carries excess body weight that may affect their health. The research evaluates a new medication called cagrilintide, which is given as an injection under the skin (subcutaneous injection) once weekly, along with lifestyle changes, to help with weight management.

The purpose of this research is to determine if cagrilintide is more effective than placebo in helping people lose weight. The study will specifically look at whether the medication can help people achieve a reduction of at least 5% of their body weight. During the study, participants will receive either cagrilintide or placebo injections for approximately 64 weeks.

The study will measure various health indicators including changes in body weight, waist size, blood pressure, and different types of cholesterol in the blood. It will also assess how the treatment affects quality of life and overall health. Throughout the study, participants’ safety will be monitored by tracking any side effects that may occur.

1 Initial assessment

Your eligibility for the study will be evaluated based on your body mass index (BMI). You need to have either:

– BMI of 30 or higher, or

– BMI of 27 or higher with at least one weight-related health condition (such as high blood pressure, sleep apnea, or heart disease)

You must be 18 years or older and have previously attempted to lose weight through diet

2 Treatment period

You will receive either cagrilintide or a placebo (substance with no active medication)

The medication will be given as an injection under the skin (subcutaneous) once per week

You will also receive guidance on lifestyle changes

The study will continue until July 2027

3 Measurements and monitoring

Throughout the study, these aspects will be measured:

– Your body weight and waist size

– Blood pressure

– Blood tests to check cholesterol, blood sugar, and other health markers

– Quality of life assessment through questionnaires

Any side effects or health changes will be recorded

4 Treatment goals

The main goals of the treatment are:

– Reducing your body weight

– Achieving at least 5% reduction in body weight

Additional goals include possible 10% and 15% weight reduction and improvements in overall health measurements

Who Can Join the Study?

Must sign an informed consent form before any study activities begin
Can be male or female
Must be 18 years or older
Must have tried at least one diet to lose weight in the past without success
Must have either:
- A Body Mass Index (BMI) of 30 or higher (BMI is a measure of body fat based on height and weight), or
- A BMI of 27 or higher with at least one weight-related health condition, such as:
  - High blood pressure (hypertension)
  - Abnormal blood fat levels (dyslipidemia)
  - Sleep apnea (breathing pauses during sleep)
  - Heart and blood vessel problems (cardiovascular disease)

Who Cannot Join the Study?

Body Mass Index (BMI) below 27 kg/m² or above 50 kg/m²
Change in body weight greater than 5% within 90 days before screening
History of bariatric surgery (weight loss surgery) or planned bariatric surgery during the trial
Current treatment with prescription medications for weight management
History of type 1 diabetes (condition where body doesn’t produce insulin)
Uncontrolled high blood pressure (above 160/100 mmHg)
History of heart attack or stroke in the past 6 months
History of pancreatitis (inflammation of the pancreas)
Current or history of eating disorders
Pregnant or breastfeeding women
Known allergies to the study medication or its components
Participation in another clinical trial within 90 days before screening
Severe kidney or liver problems
Current cancer treatment or history of cancer within past 5 years (except treated skin cancer)
History of substance abuse within the past 2 years

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Rome	Italy
NBR Polska Tomasz Klodawski	Warsaw	Poland
Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik	Bialystok	Poland
Diabeteszentrum Hamburg West	Hamburg	Germany

Other Sites

Site Name	City	Country
St. Olavs Hospital HF	Trondheim	Norway
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone	Palermo	Italy
Terpa Sp. z o.o. sp.k.	Lublin	Poland
InnoDiab Forschung GmbH	Essen	Germany
R.E.D. Institut fuer medizinische Studien und Fortbildung GmbH	Oldenburg In Holstein	Germany
Centre De Recherche Clinique Portes Du Sud	Venissieux	France
Drammen Sykehus	Drammen	Norway
Ospedale San Raffaele S.r.l.	Milan	Italy
Centre Hospitalier Universitaire De Nantes	Nantes	France
Care Clinic Sp. z o.o.	Katowice	Poland
Hvxul Bftzqq Hp	Bergen	Norway
Arpmkcj Ucxgn Snglrthtm Lcwzvs Dc Blnlcpf	Bologna	Italy

Trial status

Country	Status	Recruitment Start
France	Not recruiting	05.11.2025
Germany	Not recruiting	05.11.2025
Italy	Not recruiting	05.11.2025
Norway	Not recruiting	05.11.2025
Poland	Not recruiting	05.11.2025

Trial locations

Investigated drugs:

Cagrilintide

Cagrilintide is a new medication being studied for weight management in people who are overweight or obese. It is given as an injection under the skin (subcutaneously) once per week. This medication is designed to work alongside lifestyle changes, including diet and exercise, to help people lose weight. It belongs to a new class of medications that aim to regulate appetite and metabolism to support weight reduction.

Placebo is an inactive substance that contains no medication. In this trial, it is used as a comparison to measure how well cagrilintide works for weight management.

Both treatments are given along with lifestyle intervention counseling, which includes guidance on diet and exercise to support weight loss efforts.

Investigated diseases:

Obesity – A chronic medical condition characterized by excessive accumulation of body fat that can affect overall health. The condition develops when caloric intake consistently exceeds energy expenditure, leading to weight gain over time. Body fat accumulates throughout the body, particularly in the abdomen, under the skin, and around internal organs. Obesity is often accompanied by changes in metabolism and hormone function.

Overweight – A condition where a person’s body weight is higher than what is considered healthy for their height, but not as severe as obesity. The condition results from an energy imbalance where caloric intake exceeds the body’s energy needs. Overweight can affect body composition and may lead to increased fat storage in various parts of the body. The condition can progress gradually over time as a result of lifestyle factors and metabolic changes.

Trial ID:

2024-519530-24-00

Protocol code:

NN9833-8242

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of cagrilintide for weight reduction in adults with overweight or obesity when combined with lifestyle changes

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?